Exaluren for Alport Syndrome Kidney Disease
Part of Genetic & congenital, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests whether a new medication called exaluren can slow kidney damage in people with Alport Syndrome caused by specific genetic mutations. Alport Syndrome is a genetic condition that damages the kidneys, and this trial aims to see if exaluren can help preserve kidney function and reduce protein loss in urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Alport Syndrome with a specific nonsense mutation (a type of genetic error) in one of three genes: COL4A5, COL4A3, or COL4A4
- Your kidney function (measured by eGFR) is above 45 ml/min/1.73 m²
- You have significant protein in your urine (UPCR ≥ 500 mg/g on two separate spot urine tests)
- You have been taking an ACE inhibitor or ARB blood pressure medication on a stable dose for at least 12 weeks before starting the study
- You have not had any organ transplants, dialysis, or acute kidney injury in the past 4 weeks
- You do not have advanced liver disease (cirrhosis or portal hypertension) or liver enzyme abnormalities
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
This trial studies whether an ACE inhibitor (a blood-pressure/kidney-protecting medicine) is safe and effective for adults with Alport syndrome caused by certain COL4A3/COL4A4/COL4A5 gene variants. It aims to see if treatment can help protect kidney function in people who currently have signs like blood or small amounts of protein in the urine.
This study tests a new medicine called BAY 3401016 to see if it can help adults with Alport syndrome, a genetic condition that affects the kidneys. The drug is given as an infusion or injection and the study will check how well it works and if it is safe.
This is a registry that collects information from people with Alport syndrome to better understand the disease and how to delay kidney failure. It may help researchers learn which factors and treatments are most important over time.
This study looks at how specific genetic changes (genotypes) relate to kidney problems and urine blood findings in people with Alport syndrome. It may help doctors predict disease course and tailor care, though it may not involve new treatment.
This study follows people diagnosed with Alport syndrome to better understand the condition and its effects. It may help researchers learn what to watch for over time and how the disease progresses.
Hear when a new Alport Syndrome, X-Linked trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.